FDAnews Drug Daily Bulletin
July 20, 2012 | Vol. 9 No. 142
Drug companies’ patent settlements may no longer need clauses preventing authorized generic (AG) launches after Monday’s landmark court decision on pay-for-delay deals, a pharma lawyer says.
Drugmakers are paying anywhere from $3 billion to $5 billion annually for clinical trial procedures that may not be necessary, a new study concludes.
Eli Lilly’s antidepressant Cymbalta will remain patent protected until December 2013, now that the company has snagged an additional six months U.S. marketing exclusivity by conducting FDA-requested pediatric trials.
Four House lawmakers will introduce legislation requiring most pain drugs to adopt abuse-deterring safeguards, the broadest congressional attempt at curbing the nation’s prescription-drug problem.
A four-in-one pill cut blood pressure and cholesterol significantly in over-50s with no history of heart disease in a small British study, fuelling debate about the use of a so-called polypill to ward off heart attacks and strokes.
Johnson & Johnson’s profits are down.
The pharmaceutical industry has agreed in principle to enforce a code that will restrict them from offering gifts or other sops to doctors in order to prescribe their medicines, according to Indian Pharmaceutical Alliance.
Galena Biopharma’s shares soared Wednesday after the biopharmaceutical company announced that it has secured a new patent for the cancer therapy vaccine that it is developing.
Sanofi announced a new research collaboration with Brigham and Women’s Hospital, a teaching and research affiliate of Harvard Medical School.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.